^
Association details:
| Biomarker: | IDH1 R132V |
|---|---|
| Cancer: | Cholangiocarcinoma |
| Drug: | dasatinib (c-KIT inhibitor, Bcr-abl tyrosine kinase inhibitor, Src kinase inhibitor, EphA2 receptor antagonist, PDGFR β antagonist) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Isocitrate dehydrogenase mutations confer dasatinib hypersensitivity and SRC-dependence in intrahepatic cholangiocarcinoma
Excerpt:
To extend these findings...an additional line harboring an endogenous IDH1 R132V mutation (designated ICC5). As with our established cell lines, ICC5 cells were highly and specifically responsive to dasatinib…
DOI:
10.1158/2159-8290.CD-15-1442
